Reach Us +44-1647-403003
Molecular Engineering Of Fc Fusion Proteins To Tailor Effector Function To Clinical Indication | 40529
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Molecular engineering of Fc fusion proteins to tailor effector function to clinical indication

5th World Congress on Cancer Therapy

Steven Chamow

Chamow & Associates, Inc., USA

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.C1.057

The potential therapeutic value of many proteins—including enzymes, receptors, cytokines and peptides—can be realized by fusing these proteins to the Fc region of human immunoglobulin G. Effector functions mediated by Fc can significantly alter the biological activity of Fc fusion proteins. These functions include antibody dependent cell-mediated cytotoxicity (ADCC), which occurs through binding of the Fc domain to Fc receptors (FcR) on immune cells, as well as complementmediated cytotoxicity (CDC), induced by binding to C1q. Notably, Fc effector functions can be modulated through choice of Fc subclass, mutagenesis, and modification of oligosaccharides. The use of Fc engineering to tailor effector function to clinical indication in this drug class will be discussed.

Steven Chamow, PhD., has 28 years of experience in biopharmaceutical product development. He is currently principal consultant at Chamow & Associates, Inc., working with biotechnology companies to design and implement development strategies for new therapeutic products. During his career, he served in roles of increasing responsibility at Genentech, Scios, Abgenix, Genitope and Intradigm and has contributed to the development of three marketed products (Avastin, Natrecor, Vectibix). Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, PhD. in biochemistry), and completed postdoctoral training at the National Institutes of Health. He is author or co-author of more than 50 scientific publications and patents and serves on the editorial board of the journal mAbs. Chamow recently completed his second book (Therapeutic Fc-Fusion Proteins) published by Wiley-Blackwell and released in 2014.

Email: [email protected]

Relevant Topics